Cargando…

The analytical validation of the Oncotype DX Recurrence Score assay

In vitro diagnostic multivariate index assays are highly complex molecular assays that can provide clinically actionable information regarding the underlying tumour biology and facilitate personalised treatment. These assays are only useful in clinical practice if all of the following are establishe...

Descripción completa

Detalles Bibliográficos
Autor principal:	Baehner, Frederick L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cancer Intelligence 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045300/ https://www.ncbi.nlm.nih.gov/pubmed/27729940 http://dx.doi.org/10.3332/ecancer.2016.675

Ejemplares similares

Oncotype DX Recurrence Score in premenopausal women
por: Zhang, Shiliang, et al.
Publicado: (2022)

Population-based estimate for the correlation of the Oncotype Dx Breast Recurrence Score® result and Ki-67 IHC MIB-1 pharmDx in HR+, HER2−, node-positive early breast cancer
por: Crager, Michael, et al.
Publicado: (2022)

Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®
por: Buus, Richard, et al.
Publicado: (2021)

Correlation of Oncotype DX Recurrence Score with Histomorphology and Immunohistochemistry in over 500 Patients
por: Hanna, Matthew G., et al.
Publicado: (2017)

Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score
por: Sahebjam, S, et al.
Publicado: (2011)

Spotlight on the utility of the Oncotype DX(®) breast cancer assay
por: Siow, Zhen Rong, et al.
Publicado: (2018)

A Novel Surrogate Nomogram Capable of Predicting OncotypeDX Recurrence Score©
por: Davey, Matthew G., et al.
Publicado: (2022)

Analytical validation of the Oncotype DX prostate cancer assay – a clinical RT-PCR assay optimized for prostate needle biopsies
por: Knezevic, Dejan, et al.
Publicado: (2013)

Oncotype DX recurrence score implications for disparities in chemotherapy and breast cancer mortality in Georgia
por: Collin, Lindsay J., et al.
Publicado: (2019)

Low utility of Oncotype DX® in the clinic
por: Ricks‐Santi, Luisel J., et al.
Publicado: (2017)

Association Between Phosphorylated Histone H3 and Oncotype DX Recurrence Scores in Breast Cancer
por: Lee, Lik Hang, et al.
Publicado: (2017)

BCL-2 expression aids in the immunohistochemical prediction of the Oncotype DX breast cancer recurrence score
por: Zarella, Mark D., et al.
Publicado: (2018)

Population-based study of hormone receptor status comparing Oncotype DX with standard immunohistochemistry
por: Baehner, FL, et al.
Publicado: (2009)

MiRNA expression deregulation correlates with the Oncotype DX(®) DCIS score
por: Loudig, Olivier, et al.
Publicado: (2022)

Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey
por: Ünal, Çağlar, et al.
Publicado: (2023)

Molecular Characterization of HER2-Low Invasive Breast Carcinoma by Quantitative RT-PCR Using Oncotype DX Assay
por: Lin, Hao-Kuen, et al.
Publicado: (2023)

Examination of the Biomark assay as an alternative to Oncotype DX for defining chemotherapy benefit
por: Kim, Jinkyoung, et al.
Publicado: (2019)

MRI Radiomics and Machine Learning for the Prediction of Oncotype Dx Recurrence Score in Invasive Breast Cancer
por: Romeo, Valeria, et al.
Publicado: (2023)

Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study
por: Buus, Richard, et al.
Publicado: (2021)

Oncotype DX Breast Cancer recurrence score resists inter-assay reproducibility with RT(2)-Profiler Multiplex RT-PCR
por: Schildgen, Verena, et al.
Publicado: (2019)

Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX(® )Colon Cancer Assay
por: Clark-Langone, Kim M, et al.
Publicado: (2010)

Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis
por: Klein, Molly E, et al.
Publicado: (2013)

Breast Cancer with Low Recurrence Score on Oncotype DX(©): Interplay Between Early Recurrence, Lobular Histology and BRCA Mutation
por: Zarbiv, Yonaton, et al.
Publicado: (2022)

Oncotype DX: Where Does It Stand in India?
por: Batra, Atul, et al.
Publicado: (2019)

Impact of Oncotype DX Recurrence Score on Treatment Decisions: Results of a Prospective Multicenter Study in Turkey
por: Ozmen, Vahit, et al.
Publicado: (2016)

Verification of a Western Nomogram for Predicting Oncotype DX™ Recurrence Scores in Korean Patients with Breast Cancer
por: Kim, Jae-Myung, et al.
Publicado: (2018)

Correlative Analysis of miRNA Expression and Oncotype Dx Recurrence Score in Estrogen Receptor Positive Breast Carcinomas
por: Emmadi, Rajyasree, et al.
Publicado: (2015)

Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score(®) Test in Node-Negative Early Breast Cancer
por: Berdunov, Vladislav, et al.
Publicado: (2022)

Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data
por: Orucevic, Amila, et al.
Publicado: (2017)

Improving Therapeutic Ratios with the Oncotype DX® Ductal Carcinoma In Situ (DCIS) Score
por: Lalani, Nafisha, et al.
Publicado: (2017)

Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy
por: Buus, Richard, et al.
Publicado: (2016)

Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer
por: Dodson, Andrew, et al.
Publicado: (2017)

Oncotype Dx Results in Multiple Primary Breast Cancers
por: Toole, Michael J., et al.
Publicado: (2014)

Does Mode of Surgical Intervention Based on Oncotype DX Score Influence Disease Recurrence in Early Breast Cancer?
por: Aherne, T. M., et al.
Publicado: (2020)

Treatment decisions in estrogen receptor-positive early breast cancer patients with intermediate oncotype DX recurrence score results
por: Fried, Georgeta, et al.
Publicado: (2014)

Impact of Oncotype DX Recurrence Score on the Patterns of Locoregional Recurrence in Breast Cancer (Korean Radiation Oncology Group 19-06)
por: Kim, Kyubo, et al.
Publicado: (2020)

HER2 assessment using fluorescence in situ hybridization compared with Oncotype DX and association with risk of breast cancer death
por: Baehner, FL, et al.
Publicado: (2009)

Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer
por: Taylor, Caitlin, et al.
Publicado: (2023)

Is radiomic MRI a feasible alternative to OncotypeDX(®) recurrence score testing? A systematic review and meta-analysis
por: Davey, M G, et al.
Publicado: (2021)

Deep Learning-Based Pathology Image Analysis Enhances Magee Feature Correlation With Oncotype DX Breast Recurrence Score
por: Li, Hongxiao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7bmu61fq66dp15hbimaps6kkh1